RhumbLine Advisers
SLN

RhumbLine Advisers’s Silence Therapeutics SLN Stock Holding History

RhumbLine Advisers’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152K Sell
13,815
-120
-0.9% -$844 ﹤0.01% 3391
2026
Q1 		$73.4K Buy
13,935
+936
+7% +$5.15K ﹤0.01% 3513
2025
Q4 		$79K Buy
12,999
+7,134
+122% +$45.7K ﹤0.01% 3545
2025
Q3 		$30.4K Sell
5,865
-331
-5% -$1.84K ﹤0.01% 3728
2025
Q2 		$35.9K Buy
6,196
+4,321
+230% +$18.5K ﹤0.01% 3723
2025
Q1 		$5.28K Buy
1,875
+1,034
+123% +$5.05K ﹤0.01% 3897
2024
Q4 		$5.78K Buy
841
+87
+12% +$1.12K ﹤0.01% 3935
2024
Q3 		$13.7K Buy
754
+285
+61% +$5.3K ﹤0.01% 3853
2024
Q2 		$8.91K Buy
469
+454
+3,027% +$9.65K ﹤0.01% 3998
2024
Q1 		$324 Buy
15
+10
+200% +$217 ﹤0.01% 4200
2023
Q4 		$86 Hold
5
– – ﹤0.01% 4251
2023
Q3 		$49 Buy
+5
New +$37 ﹤0.01% 4290

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

RhumbLine Advisers's SLN Position: Q2 2026 in Review

RhumbLine Advisers reduced its Silence Therapeutics (SLN) stake by 0.86% in Q2 2026, selling an estimated $844 and leaving 13,815 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

RhumbLine Advisers first reported a position in SLN in Q3 2023 and has held it in 12 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • RhumbLine Advisers held 13,815 shares of Silence Therapeutics worth $152K as of Q2 2026.
  • RhumbLine Advisers sold 120 Silence Therapeutics shares in Q2 2026, an estimated $844.
  • Silence Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3391 holding.
  • RhumbLine Advisers first reported a position in Silence Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.